Your browser doesn't support javascript.
loading
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel.
Miner, Maurine D; Hatherill, Mark; Mave, Vidya; Gray, Glenda E; Nachman, Sharon; Read, Sarah W; White, Richard G; Hesseling, Anneke; Cobelens, Frank; Patel, Sheral; Frick, Mike; Bailey, Theodore; Seder, Robert; Flynn, Joanne; Rengarajan, Jyothi; Kaushal, Deepak; Hanekom, Willem; Schmidt, Alexander C; Scriba, Thomas J; Nemes, Elisa; Andersen-Nissen, Erica; Landay, Alan; Dorman, Susan E; Aldrovandi, Grace; Cranmer, Lisa M; Day, Cheryl L; Garcia-Basteiro, Alberto L; Fiore-Gartland, Andrew; Mogg, Robin; Kublin, James G; Gupta, Amita; Churchyard, Gavin.
Afiliação
  • Miner MD; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Mave V; Johns Hopkins India, Byramjee-Jeejeebhoy Government Medical College Clinical Research Site, Pune, India.
  • Gray GE; South African Medical Research Council, Cape Town, South Africa.
  • Nachman S; Department of Pediatrics, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.
  • Read SW; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • White RG; Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
  • Hesseling A; Desmond Tutu Tuberculosis Centre, Stellenbosch University, Stellenbosch, South Africa.
  • Cobelens F; Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
  • Patel S; US Food and Drug Administration, Silver Spring, MD, USA.
  • Frick M; Treatment Action Group, New York, NY, USA.
  • Bailey T; Greater Baltimore Medical Center, Baltimore, MD, USA.
  • Seder R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Flynn J; Microbiology and Molecular Genetics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Rengarajan J; Emory School of Medicine, Emory University, Atlanta, GA, USA.
  • Kaushal D; Texas Biomedical Research Institute, San Antonio, TX, USA.
  • Hanekom W; Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.
  • Schmidt AC; Gates Medical Research Institute, Boston, MA, USA.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Nemes E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Andersen-Nissen E; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Cape Town HIV Vaccine Trials Network (HVTN) Immunology Laboratory, Cape Town, South Africa.
  • Landay A; Rush Medical Center, Chicago, IL, USA.
  • Dorman SE; Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
  • Aldrovandi G; Department of Pediatrics, University of California, Los Angeles, CA, USA.
  • Cranmer LM; Emory School of Medicine, Emory University, Atlanta, GA, USA.
  • Day CL; Emory School of Medicine, Emory University, Atlanta, GA, USA.
  • Garcia-Basteiro AL; ISGlobal, Hospital Clínic Universitat de Barcelona, Barcelona, Spain; Centro de investigação de Saúde de Manhiça, Maputo, Mozambique.
  • Fiore-Gartland A; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Mogg R; Takeda Pharmaceutical Company, Cambridge, MA, USA.
  • Kublin JG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gupta A; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Churchyard G; The Aurum Institute, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa; Department of Medicine, Vanderbilt University, Nashville, TN, USA. Electronic address: gchurchyard@auruminstitute.org.
Lancet HIV ; 9(11): e791-e800, 2022 11.
Article em En | MEDLINE | ID: mdl-36240834
ABSTRACT
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-induced immune responses. To address the gaps in developing tuberculosis vaccines for people with HIV, a series of symposia was held that posed six framing questions to a panel of international experts What is the use case or rationale for developing tuberculosis vaccines? What is the landscape of tuberculosis vaccines? Which vaccine candidates should be prioritised? What are the tuberculosis vaccine trial design considerations? What is the role of immunological correlates of protection? What are the gaps in preclinical models for studying tuberculosis vaccines? The international expert panel formulated consensus statements to each of the framing questions, with the intention of informing tuberculosis vaccine development and the prioritisation of clinical trials for inclusion of people with HIV.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Infecções por HIV / Vacinas contra a Tuberculose / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Infecções por HIV / Vacinas contra a Tuberculose / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article